Mission
How we can help
Pharmaceutical & Biotech Companies
Healthcare Professionals
Patient Groups
Patients
Services
Clinical Trial Services >
Comparator Sourcing and Ancillary Supply
Direct-to-site
Demand Driven Labelling & Distribution
Investigator Initiated Trials
Technical Consultancy
Unlicensed Medicines >
Policy Development
Asset Strategy
Early Access
Real World Evidence
Post-Trial Access
Phased Launch and Non-Launch Markets
Medicine Shortages
Market Withdrawal/ Discontinuations
Consulting Services
Commercial Medicines >
Clinigen Owned Medicines
Partnering with Clinigen
Information for…
Healthcare Professionals
Patient Groups
Patients
Global offices
Australia & New Zealand
Japan
Singapore
South Africa
United Kingdom
United States
Investors
At a Glance
Financial Highlights
Investment Case
Business Model
Market Overview
Strategy
Our Businesses
Share tools
Results, Reports and Presentations
Quantum Archive
Financial Calendar
Press Releases
Press Releases
Regulatory News
Email Alerts
Shareholder Services
AGM
Registrar Services
Major Shareholders
Advisor Contacts
Analyst Coverage
AIM Rule 26
Corporate Governance
Corporate Governance Statement
Board of Directors
Company
About Clinigen >
History
Responsible business
Operational excellence
Our brands
Careers >
Frequently Asked Questions
Apply Online
Newsroom
Video Library
Press Releases
Insights and Events
Cliniport medicine finder
Clinigen France
Clinigen Germany
Get in touch
hamburger-icon
Menu
Get in touch
Close
Mission
How we can help
How we can help
Pharmaceutical & Biotech Companies
Healthcare Professionals
Patient Groups
Patients
Services
Services
Clinical Trial Services >
Clinical Trial Services >
Clinical Trial Services >
Comparator Sourcing and Ancillary Supply
Direct-to-site
Demand Driven Labelling & Distribution
Investigator Initiated Trials
Technical Consultancy
Unlicensed Medicines >
Unlicensed Medicines >
Unlicensed Medicines >
Policy Development
Asset Strategy
Early Access
Real World Evidence
Post-Trial Access
Phased Launch and Non-Launch Markets
Medicine Shortages
Market Withdrawal/ Discontinuations
Consulting Services
Commercial Medicines >
Commercial Medicines >
Commercial Medicines >
Clinigen Owned Medicines
Partnering with Clinigen
Global offices
Global offices
Australia & New Zealand
Japan
Singapore
South Africa
United Kingdom
United States
Investors
Investors
At a Glance
Financial Highlights
Investment Case
Investment Case
Investment Case
Business Model
Market Overview
Strategy
Our Businesses
Share tools
Results, Reports and Presentations
Quantum Archive
Financial Calendar
Press Releases
Press Releases
Press Releases
Regulatory News
Email Alerts
Shareholder Services
Shareholder Services
AGM
Registrar Services
Major Shareholders
Advisor Contacts
Analyst Coverage
AIM Rule 26
Corporate Governance
Corporate Governance
Corporate Governance Statement
Board of Directors
Company
Company
About Clinigen >
About Clinigen >
About Clinigen >
History
Responsible business
Operational excellence
Our brands
Careers >
Careers >
Careers >
Frequently Asked Questions
Apply Online
Newsroom
Newsroom
Video Library
Press Releases
Insights and Events
Cliniport medicine finder
Global sites
Clinigen France
Clinigen Germany
Submit
Press Releases
2018
2017
2016
2015
Archive
More
Filter by
All
Business
Financial
Idis Global Access
12 Apr 2018
Clinigen receives PBS listing for TREXJECT® (methotrexate) in Australia for the treatment of rheumatoid arthritis and psoriasis
Related materials
PDF
(215.41KB)
19 Mar 2018
Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos® (CPX-351) outside the United States
06 Mar 2018
Clinigen strengthens senior management team in Clinical Trial Services and Commercial Medicines
27 Feb 2018
Half Year Results for the Six Months Ended 31 December 2017
Related materials
PDF
(1.33MB)
Presentation
(pdf 2.05MB)
20 Feb 2018
Clinigen and Santhera launch US Expanded Access Program with Idebenone for patients with Duchenne Muscular Dystrophy
06 Feb 2018
Notification of Half Year Results Date
Load more
